Tempus AI has announced an expanded collaboration with Takeda to enhance oncology research and development.
The partnership aims to leverage Tempus’ multimodal real-world datasets and biological model systems to advance Takeda’s cancer therapy pipeline.
Following an initial collaboration using Tempus’ de-identified datasets, the new agreement will see Takeda combine these datasets with Tempus’ biological modelling capabilities.
This will support the development of Takeda’s cancer therapeutics portfolio, including small molecules, antibody-drug conjugates, bispecifics and gamma delta T-cell therapies.
Utilising Tempus’ analytics platform, Lens, Takeda researchers will access de-identified patient records and AI-enabled tools. These resources are expected to accelerate insights for drug development.
The initial phase of the collaboration has already yielded research which will be presented at a forthcoming medical congress.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Tempus chief operating officer Ryan Fukushima stated: “We are excited to expand our relationship with Takeda, combining real-world multimodal data and biological modeling capabilities to better understand targets of interest.
“The results we’ve seen thus far demonstrate how the collaboration between the Takeda and Tempus teams can assist in efforts to accelerate Takeda’s growing oncology therapeutic pipeline, which may lead to the next generation of cancer treatments.”
Concurrently, Tempus and Takeda have started a multi-phase biological modelling project. Utilising a vast repository of patient-derived tumour organoids, the project aims to enhance drug effectiveness predictions.
The collaboration will focus on a panel of 60 organoids across ten cancer types to evaluate preclinical candidates.
In May 2024, Takeda disclosed a significant profit decrease of more than 50% for the fiscal year 2023. The company has announced plans to optimise its workforce and prioritise its research and development pipeline in response to these financial challenges.
